NEW
Allfastra SARS-CoV-2/FluA/FluB/RSV Real Time PCR Kit
Prepare for the COVID-19 pandemic and winter viruses season with a reliable multiplex assay to detect and distinguish 4 viruses.
Monkeypox Virus Diagnostic Solution
With increasing confirmed monkeypox cases, more people, countries, and regions are at risk of infection. Nowadays, confirmed cases of infants and cases in schools have been reported; the monkeypox virus has spread among vulnerable individuals, indicating great urgent demand for early diagnosis. Bioperfectus provides FIVE kits for humans with a CE certificate and ONE kit for veterinary use, presenting a rapid response to help diagnose monkeypox infection as early as possible.
COVID-19 Diagnostic Solution
Although the number of new coronavirus cases fell everywhere in the world, the global pandemic is not over. Bioperfectus continues to provide you with a comprehensive range of products for COVID-19 diagnosis and confirmation, including the antigen rapid tests, antibody rapid test and RT-PCR tests, to safeguard your health.
Cervical Cancer Screening Solution
With over 600 thousand new cases and more than half that would lead to death yearly, cervical cancer is listed as NO.4 cancer among women worldwide. Lack of screening and treatment leads to higher rates of incidence and mortality. Bioperfectus is confident in providing products, supporting tests for cervical swabs, and liquid-based cytology samples with solid results, enabling women to get access to screening and diagnosis at the early stage of HPV infection before the development of precancerous lesions and cervical cancer.
SAW-96
SAW-96 is an automated nucleic acid extraction workstation, which integrates sample loading, nucleic acid purification, and PCR setup functions in one instrument. The run duration is less than 70 minutes for 1-96 samples. Based on experienced magnetic separation technology, SAW-96 provides high throughput automation combined with high performance.
Total PCR Solution
Bioperfectus Total PCR Solution offers holistic products of extraction systems, extraction reagents, real-time PCR systems, and RT-PCR reagents. The automatic solution could help customers to establish a highly efficient PCR workflow and release the labor.

Jiangsu Bioperfectus Technologies Co., Ltd.

(SSE:688399)

Since its founding in 2010, BioPerfectus has been dedicated to providing molecular diagnostic solutions specializing in emerging infectious diseases for generations and generations to come. We are leading the change by offering Real-Time PCR Kits, Nucleic Acid Extraction Systems, Automation Solutions, and Rapid Tests to laboratories, hospitals, institutions, and CDCs across the globe. BioPerfectus products have been distributed to more than 100 countries around the world. As one of the leading global IVD suppliers, BioPerfectus is committed to delivering excellent services and products that meet the highest international quality and safety standards. Our global presence enables us to build close relationships with our clients and leverage our expertise to support them worldwide.

62,000 +㎡

An industrial park of over 62,000㎡ integrating fully self-innovative R&D, production, warehousing, logistics, sales, marketing and customer service divisions catering for various business scenarios

800 +

Over 800 Bioperfectus people’s permission gathering the perseverance and determination to fight against the global pandemic

5,000,000 +

Production capacity ramping up to more than 5 million tests/day ensuring the quick sufficient response to infectious diseases

global presence

90 Countries within a year

Bioperfectus Products & Service have been distributed to over 80+ countries around the globe within only one year since the international business established.

20000 Installation base

Bioperfectus Nucleic Acid Extraction Solutions
were launched in over 20,000 laboratories
globally with a well-trained and quick-response
customer service team.

Product Center
News Center
12-262022
Announcing BioPerfectus New Brand Identity
Announcing BioPerfectus New Brand Identity
12-262022
We are delighted and proud to unveil our new brand identity, which perfectly reflects the evolution of our company since it was established in 2010. After many years of rapid development and transformation, the strong desire for innovation has contributed to this re-branding plan - this is a critical period of transformation.BioPerfectus will start the next "golden decade" with a new attitude and adopt a more international logo in a broader commercial market.We aim to create a stronger image that would build on the previous one and accurately describe who we are today: one of the global IVD suppliers with a mission to embrace the world with health. In 2020, the BioPerfectus International Sales Marketing Division was established, making its official foray into the global market. Since then, BioPerfectus has rapidly expanded its network in the global market and obtained 216 overseas regulatory certificates for market access, including WHO-EUL, FDA-EUA, CE Mark, etc. BioPerfectus products have been distributed to more than 100 countries around the world. As a leading global company in the molecular diagnostics market,BioPerfectus has continuously expanded its breadth and depth of experience as it supports partners worldwide to prevent and control infectious diseases.BioPerfectus, in close collaboration with many governments and non-governmental organizationsworldwide, has built professional and well-trained response teams to ensure readiness for emergency outbreaks in public health.BioPerfectus remains committed to delivering excellent services and products that meet the highest international quality and safety standards. The CEO of BioPerfectus, Dr. Guoqiang Wang, said, This change was inevitable.What changes is the perspective and strength of the company, but what remains unchanged is the original intention. The implied meaning of BioPerfectus represents that life technology makes the world better.The "b" - bio and "p" - perfect highlight the individuality and exclusivity of BioPerfectus, which also implies the company's global vision. The letter combination of "b" and "p" resembles a cell structure that is undergoing replication and division. The "b" is the primitive cell in the primary stage, which is a metaphor for the internal strength and foundation of the enterprise. The "p" is the new cell of differentiation and fission, which means the never-ending entrepreneurial spirit. The two are independent yet complement each other, presenting a dynamic "separation" and "combination, conveying the critical message in a precise and innovative visual manner. The connotation represents inclusiveness, multiculturalism, and embracing outstanding talents for corporate innovation, promoting the growth of the medical industry and protecting human health. We are eager to have a deeper and closer connection with our partners. We have worked closely with our partners to give full play to the advantages and innovation of BioPerfectus, and jointly solve the problems that threaten human survival and life health.The 21st century is the century of life science. "Jointly creating a future without disease" emerges as the ultimate goal of modern medicine and also the commitment of BioPerfectus. In the future, BioPerfectus will continue to improve the brand value and share of voice and other aspects to achieve comprehensive leaps and long-term improvement and initiate the new branding strategy to embrace brilliance actively. The new version of LOGO will be applied to the products, packaging, and dissemination of the belonging series and will gradually come to users in the future.
10-252022
Bioperfectus and World Health Organization (WHO) Collaborate on Molecular Diagnostics
Bioperfectus and World Health Organization (WHO) Collaborate on Molecular Diagnostics
10-252022
A batch of Bioperfectus-developed Nucleic Acid Extraction System SSNP-2000B began shipping today to World Health Organization (WHO). The distribution of Bioperfectus SSNP-2000B Nucleic Acid Extraction System will support the development of molecular diagnostics in Africa. Bioperfectus SSNP-2000B Nucleic Acid Extraction System is a laboratory medical device thatintegrates mechanism and electrical automation,and computer software to enable automatic nucleic acid extraction of 32 samples maximumly in one time. The instrument won theworld-renowned iF DESIGN AWARD 2022in recognition of its unique structure and innovative design. During the COVID-19 pandemic, Bioperfectus supported WHO in responding to the COVID-19 crisis by delivering test kits and training for health professionals worldwide. Bioperfectus is proud to continue collaborating with WHO as an IVD supplier in molecular diagnostic projects. Molecular diagnostics plays a vital role in infectious disease detection, case management, surveillance, and a supporting role in therapeutic and vaccine trials. Bioperfectus is committed to providing laboratories with more efficient and accurate diagnosis solutions. SSNP series, as an important part of the Bioperfectus extraction product portfolio, allows customers to have more flexible choices based on their sample throughput. Three SSNP extraction systems of different throughputs provide multiple choices for the laboratory. The optional throughputs vary from 32 to 96 channels. With pre-programmed protocols and pre-filled kits, it is very easy and highly efficient to operate. And it only takes less than 15 minutes to complete the extraction process.All models are equipped with HEPA filter-independent air path in which the biological filter cotton can absorb the nucleic acid aerosol. Bioperfectus provides a total PCR solution with automated instruments and abundant reagent panels. Total PCR solution will help you automate your lab, free up human labor and save costs. Pioneering in molecular diagnostics, Bioperfectus is always devoted to pursuing high quality, innovating, and striving to solve health problems humanity faces for a healthier future.
11-302022
Bioperfectus Supports Cholera Elimination
Bioperfectus Supports Cholera Elimination
11-302022
SHANGHAI, CHINA, December 5, 2022Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as Bioperfectus) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance. Cholera is an acute diarrheal infection caused by ingestion of food or water contaminated with the bacterium Vibrio cholerae. There are many serogroups of V. cholerae, but only two O1 and O139 cause outbreaks. V. cholerae O1 has caused all recent outbreaks. About 20% of those who are infected with V. cholerae develop acute watery diarrhea; approximately 20% of these individuals develop severe watery diarrhea, many also with vomiting. If these patients are not promptly and adequately treated, the loss of fluid and salts can lead to severe dehydration and death within hours. The case fatality rate in untreated cases may be 3050%. Researchers have estimated that each year there are 1.3 to 4.0 million cases of cholera and 21 000 to 143 000 deaths worldwide due to cholera. Cholera remains a global threat to public health and an indicator of inequity and lack of social development. Bioperfectus provides Vibrio Cholerae Real Time PCR Kits including ONE kit for human diagnosis with a CE certificate and ONE kit for environmental surveillance use to support early detection of Vibrio cholerae infection and improve early warning surveillance. Both of them are based on real-time PCR technology, for the detection of DNA from Vibrio Cholerae O1, Vibrio Cholerae O139 and Vibrio Cholerae. V. cholerae spreads through water contaminated with feces. The aquatic environment, especially surface waters and stored drinking water, is a key component of the cholera transmission chain. To date, sampling of V. cholerae in environmental and/or sewage water has been used in different contexts applying various methods. To distinguish non-toxigenic environmental strains from toxigenic strains circulating during an outbreak, identification should include O1 serogroup determination and be completed by Polymerase Chain Reaction (PCR) identification of the cholera toxin genes. The combination use of these two products can highly improve efficiency from prevention to early detection, to narrow the transmission scale as early as possible. Bioperfuctus, a one-stop supplier specializing in molecular diagnostics, highly recommends the Total PCR Solution for Gastrointestinal Infectious disease, with higher throughput and higher efficiency. Dedicated to providing laboratories with comprehensive tests of Gastrointestinal Infectious disease, Bioperfectus provides the 𝐓𝐨𝐭𝐚𝐥 𝐏𝐂𝐑 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 with instruments and kits. Pioneering in molecular diagnostic, Bioperfectus are always devoted to pursuing high quality, keeps innovating, and strives to solve health problems faced by humankind for a healthier future. 𝖱𝖾𝖿𝖾𝗋𝖾𝗇𝖼𝖾: [𝟣] https://www.who.int/news-room/fact-sheets/detail/cholera?gclid=Cj0KCQiAj4ecBhD3ARIsAM4Q_jH7qVKuIvE3-gFOip6hkAoJmCbYeoQSQiNYE34jQoI7LlkKUDZDe_EaArgtEALw_wcB [2]https://www.gtfcc.org/wp-content/uploads/2022/10/gtfcc-technical-note-environmental-surveillance-for-cholera-control-october-2022.pdf
Service Network
Support is only one step away
A good after-sales service is essential for efficiency of workload in PCR laboratory. Bioperfectus delivers most perfect service via our authorized distributors and global service center. With well-experienced service staff, sufficient spare-part inventory and fast global logistics, Bioperfectus aims to provide with the satisfactory solutions to our end users.We offer 24/7 after-sales service, prompt response and periodical training programs.
CONTACT US NOW